In a fit of boundless national optimism, Peugeot and Renault (and a few years later Volvo) teamed up to make a new V8 for good power and performance. But that's not what the world got. We welcomed in ...

While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. Since ...

Privo Technologies, Inc., today announced that the first patient has been dosed in its first-in-human clinical trial evaluating PRV131 ...

For Americans living with rare diseases, the Rare Pediatric Disease Priority Review Voucher Program is a vital tool. Yet its reauthorization is at risk.

The U.S. House of Representatives has given a unanimous thumbs-up to the Give Kids A Chance Act, which would revive the FDA’s rare pediatric review voucher program following its expiration in December ...

PRV RENAMED: What's in a name? Apparently something, at least in the view of the U.S. Air Force, which says it is changing the name of the Personnel Recovery Vehicle (PRV) program to Combat Search and ...

Incentive scheme for rare disease drug development vital for sector, says leading biotechSynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the ...

After gaining FDA approval for Miplyffa ® (arimoclomol) as the first-ever therapy indicated to treat Niemann-Pick disease type C (NPC), Zevra Therapeutics has cashed in on the regulatory win by ...

TALLAHASSEE, FL / ACCESSWIRE / February 5, 2021 / Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as ...